review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | F W A Verheugt | |
P2860 | cites work | Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial | Q44672192 |
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial | Q45258336 | ||
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study | Q56680969 | ||
Good old warfarin for stroke prevention in atrial fibrillation | Q83963699 | ||
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial | Q26248603 | ||
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force | Q28192096 | ||
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial | Q28193437 | ||
Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation | Q28201331 | ||
Stroke prevention in elderly patients with atrial fibrillation | Q28219361 | ||
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial | Q28219363 | ||
Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin | Q33671179 | ||
Antithrombotic therapy for atrial fibrillation | Q33812662 | ||
The natural history of lone atrial fibrillation. A population-based study over three decades | Q34186025 | ||
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study | Q34186228 | ||
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial | Q34607209 | ||
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty | Q34789112 | ||
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty | Q34789118 | ||
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial | Q34789474 | ||
Anticoagulants in heart disease: current status and perspectives | Q36787643 | ||
P433 | issue | 6 | |
P921 | main subject | anticoagulation | Q63279445 |
P304 | page(s) | 314-318 | |
P577 | publication date | 2010-06-01 | |
P1433 | published in | Netherlands Heart Journal | Q2146163 |
P1476 | title | The new oral anticoagulants | |
P478 | volume | 18 |